i-sense: EPSRC IRC in Agile Early Warning Sensing Systems for Infectious Diseases and Antimicrobial Resistance

Lead Research Organisation: University College London
Department Name: London Centre for Nanotechnology

Abstract

In 2017 the need for disruptive sensing systems to detect and limit infectious outbreaks has taken centre stage - Zika virus and Ebola add to the threat of pandemic influenza, HIV and antimicrobial resistance, for which the world remains unprepared. Infections are a global problem and our response must therefore be global in nature. The House of Commons Ebola report recognised the 'heroic' work of scientists, researchers and agencies but highlighted that 'the UK response - like the international response - was undermined by systemic delay' and 'we must take the opportunity now to ensure that the UK is not caught unprepared when the next disease emergency strikes. Lives can be lost for every day of delay.'

The i-sense2 EPSRC IRC aims to engineer a new generation of agile and globally impactful early warning sensing systems for infectious diseases and antimicrobial resistance. We are harnessing the power of mobile phones, biomedical engineering, nanotechnology, genomics and big data to detect outbreaks much earlier than ever before. Next Steps funding is pivotal to; maximising the impact of our current IRC research programme, retaining key staff and delivering a step change in our capabilities to respond to emerging infections and antimicrobial resistance. This will in-turn leverage over £10M in translational 'test bed' infrastructure, new laboratories, academic positions, studentships and industry partnerships to help ensure our sustainability as a National Centre of Excellence.

We will build on our pioneering work within our current i-sense IRC which focused on three infectious diseases - influenza, HIV and C. difficile. The step change we now propose is to engineer more 'agile' systems that are rapidly adaptable to different diseases, antimicrobial resistant strains and different countries. Recognising the need to develop new systems through an understanding of context, i-sense2 brings together multiple disciplines, Public Health England, the Africa Health Resarch Institute, the Royal College of General Practitioners Research Surveillance Centre, the NIHR UCLH Biomedical Research Centre, and industry to:

1. Harness deep learning of millions of symptoms reported online (e.g. social media, searches) to track outbreaks, potentially before people visit their doctors and in resource-limited settings;
2. Build smartphone connected diagnostic tests to support front-line health-workers and self-testing. We will develop low-cost biobarcode paper microfluidic tests and handheld sequencing technologies to detect the earliest biomarkers of infection and drug-resistance, and securely send results to online infectious disease clinics;
3. Create state-of-the-art visualisation tools to link patients to treatment and map disease 'hot spots' by fusing mHealth, genomic, clinical and epidemiological data;
4. Invest in the careers of our talented researchers to become future leaders;
5. Grow a National Centre of Excellence supported by a plurality of funding.

Our disease focus will expand to influenza-like-illnesses, sexually transmitted infections and resistant-bacteria, as exemplars of acute, chronic and emerging infections. We will build population-level 'test beds' in the UK and South Africa, to pilot our technologies and then bid for next stage translational funding for clinical trials and product development. Future 'IRC Next Steps Plus Awards' will explore new research directions e.g. sensing systems for Ebola and Zika virus.

i-sense2 has the potential to bring major human and economic benefits to millions of people worldwide. Patients will benefit from receiving faster access to potentially life-saving treatment. Populations will benefit from reduced disease transmission, health systems will benefit from rapid diagnostics, and patient self-management. Industry will benefit from skilled people and new commercial opportunities. Public health will benefit from more timely interventions and pandemic preparedness.

Planned Impact

The i-sense2 EPSRC IRC will combine cutting-edge UK research with world-leading partners to bring significant benefits to patients, the public, the NHS, Public Health England, the Africa Health Research Institute, industry, government, policy makers and regulators:

i. Patient benefit - The major beneficiaries will ultimately be patients who will benefit from rapid and reliable diagnosis of infection, and fast access to effective life-saving treatments with reduced morbidity or mortality, and improvements in quality of life.

ii. Public good - The public will benefit since early detection and diagnosis tends to curb the spread of infectious diseases, preserving the effectiveness of antimicrobials for future generations.

iii. NHS and global healthcare systems - will benefit from improved service delivery and sustainable models of community care. Widening access to testing for infectious diseases and AMR in community settings will enable more patients be tested and will increase the likelihood of identifying patients at an early acute stage where the risk of onwards transmission is high. Currently, unacceptably high numbers infections are undiagnosed or diagnosed at a late stage. Early diagnosis will enable more prompt treatment (improving health outcomes) and prevent onwards transmission. This could potentially reduce the economic cost of infectious diseases on the NHS and global healthcare system - for example, reducing hundreds of thousands of flu-related NHS GP appointments each winter, and reducing treatment costs (South Africa spends $1B per annum on HIV antiretroviral treatments). Moreover, the O'Neill Report suggests that rapid tests and better diseases surveillance, together with new antimicrobial treatments, could help to avert the estimated 10 million annual deaths related to AMR infections by 2050.

iv. Public-health benefits - include new tools to harness of millions of symptoms reported online, smartphone connected diagnostic self-tests, whole genome sequencing and data visualisation tools could transform the "active" real-time surveillance of infectious diseases and antimicrobial resistance, even for patients who do not attend clinics or from geographical regions outside the remit of conventional surveillance systems. Public Health England, the Africa Health Research Institute and global public health bodies, will benefit from the proposed early-warning sensing systems, enabling them to make more rapid, evidence-based clinical interventions and monitor the effect of these strategies in real-time

v. Commercial benefits - Beyond trained personnel, the potential commercial benefits to the UK and South Africa accrue through better population testing, prevention and care, and new employment opportunities in the emerging flourishing digital economy sector. Through our first workshop, planned at the end of year 1, we will reach out to industry and SMEs, including diagnostic test manufacturers, mobile network providers, handset manufacturers, app developers, policy makers and regulators to communicate developments in our understanding of the needs and technology developments to meet them and this will seed new collaborations, particularly with the digital, molecular and sequencing companies. The UK is at the forefront of the digital economy and 5G communication, and is well placed to grow commercial opportunities in this space. The work of i-sense2 will have commercial value and we will actively seek to exploit IP in conjunction with the partner institution Technology Transfer Offices - indeed spin outs and wealth creation for the UK will, in itself, form a major deliverable for i-sense2.

vi. Government, Policy Makers, Regulators and the media will benefit from balanced information about the facilitators and barriers to adoption and implementation of new products and practices, with the goal of responsible research innovation and lowering barriers to market entry for test developers and adoption.

Publications

10 25 50
 
Description i¬sense EPSRC IRC: Agile Early Warning Sensing Systems for Infectious Diseases and Antimicrobial Resistance (EP/R00529X/1) builds of the research and outcomes from the original EPSRC grant, i-sense EPSRC IRC Early-Warning Sensing Systems for Infectious Disease (EP/K031953/1). This follow on funding also includes two IRC Plus Awards, including 'A smartphone powered mRNA sequence detector' (EP/R018707/1) led by Imperial College London, and Ultra-sensitive enhanced nanosensing of antimicrobial resistance (u-Sense) (EP/R018391/1), led by Newcastle University. Since i¬sense began in 2013, infectious diseases have taken centre stage ¬ Covid-19, Ebola, Zika and AMR have joined the threats of pandemic influenza and HIV - diseases for which the world remains unprepared. i-sense brings together a remarkably strong team of researchers from five universities with the unique interdisciplinary skills sets and leadership to build the research foundations of disruptive twenty-first century digital sensing systems for infectious diseases. Highlights include: machine learning models of online symptoms adopted for national influenza surveillance, IP for nanomaterials for ultrasensitive antigen detection, smartphone apps, online patient pathways, 'HIV test and treat' public health dashboard in South Africa, IP for IDRIS biomarker discovery for C. difficile, and smartphone test for Ebola serology piloted in Uganda. Carrying this work forward into i-sense Next Steps, we are building the i-sense programme into building an international Centre for Excellence. The objectives of i-sense Next Steps include engineering more 'agile' sensing systems to rapidly adapt to different diseases, drug-¬resistant strains and decentralised settings through: (i) Deep learning models to track millions of symptoms reported online; (ii) Smartphone-connected diagnostics with molecular capabilities, to widen access to testing and diagnose the earliest stages of infection; (iii) Data visualisation to support faster linkage to care and identify disease 'hot spots' by fusing syndromic, mHealth, genomic, clinical, epidemiological data; (iv) Investing in the careers of our talented researchers to become future leaders; (v) Growing a National Centre of Excellence with a plurality of funding. Key developments on this project include our (i) AI algorithms for flu surveillance being used by PHE in their weekly and annual flu reports; (ii) working with PHE to adapt our flu surveillance models for surveillance of Covid-19; (iii) working with UCLH to develop real-time data dashboards for hospital surveillance; and (iv) developing strong links with University of Strathclyde to develop a new type of rapid diagnostic system to detect and identify antimicrobial resistance.
Exploitation Route Important collaborations are already developing for use of our technologies by public health.
Sectors Communities and Social Services/Policy,Digital/Communication/Information Technologies (including Software),Healthcare,Pharmaceuticals and Medical Biotechnology,Other

 
Description BRC Funding for i-sense 2 Project III Theme
Amount £173,315 (GBP)
Funding ID BRC500/III/RMcK/101350 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 10/2019 
End 03/2022
 
Description IRC Next Steps Plus: A Smartphone Powered mRNA Sequence Detector
Amount £1,027,001 (GBP)
Funding ID EP/R018707/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 09/2018 
End 09/2021
 
Description IRC Next Steps Plus: Ultra-Sensitive Enhanced NanoSensing of Anti-Microbial Resistance (u-Sense).
Amount £1,388,114 (GBP)
Funding ID EP/R018391/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 10/2018 
End 08/2022
 
Description Lecturer Helthcare Disgnostics
Amount £186,504 (GBP)
Organisation University College London 
Sector Academic/University
Country United Kingdom
Start 10/2018 
End 07/2021
 
Description UKRI Centre for Doctoral Training in AI-enabled healthcare systems
Amount £6,684,742 (GBP)
Funding ID EP/S021612/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 03/2019 
End 09/2027
 
Description Africa Health Research Institute 
Organisation Africa Health Research Institute
Country South Africa 
Sector Charity/Non Profit 
PI Contribution current close working relationship between AHRI and UCL and represents a key strategic initiative to extend collaborations in education, research, business and healthcare, within the global health sector. AHRI will provide the necessary resources to facilitate this project in order to accomplish its objectives. As AHRI Chief Scientific Officer I am highly supportive of the goals outlined in this proposal and the opportunity to enable the highest calibre science to be brought to bear on a population with the most significant burden of need.
Collaborator Contribution The ability to link clinical and laboratory-based studies with social science, health systems research and population health data maximizes the potential to undertake biological, causal and interventional research at AHRI. The laboratory base in Durban is currently expanding, in collaboration with other partners, to facilitate human and pathogen genomics underpinned by high-level bioinformatics, biomarker screening, and pathogenesis research. Data, including extensive Department of Health patient records, is singly managed within a health informatics data repository. This maximises the opportunity for understanding the health of the surveillance population, and in conducting intervention studies to mitigate the adverse impact of the HIV/TB epidemics through improved treatment and care of affected individuals. It is this setting which provides a major opportunity to explore the best approach to visualisation of such complex data with impact of using innovative technology to support HIV prevention in South Africa. Basing this research within our setting ensures a rapid route to impact, as well as policy change.
Impact On-going
Start Year 2014
 
Description Cambridge Life Sciences 
Organisation Cambridge Life Sciences Ltd
Country United Kingdom 
Sector Private 
PI Contribution Collaborated with Newcastle University on Biosensors and immunosensor projects
Collaborator Contribution Technical Director will act in an advisory capacity on senior design and manufacture and also conducting market research for relevant applications including technology being developed into key commercial target areas
Impact None as of yet
Start Year 2017
 
Description Collaboration with Imperial College 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Prof. Stevens is currently Professor of Biomedical Materials and Regenerative Medicine at Imperial College London in the Department of Materials, Department of Bioengineering and Institute of Biomedical Engineering. She has excellent support on the Departmental level that provides access to state-of-the-art equipment and instrumentation, such as the Harvey Flowers Characterisation suite. Her research programme is housed within 500m2 of space on most of the 6th floor within the Institute of Biomedical Engineering, which includes dedicated space for synthetic as well as biological studies. She also has a room dedicated to Raman spectroscopic studies, along with access to facilities and core support such as histological analyses, FACS, cleanroom facilities and confocal microscopy. In addition, she has a satellite group in the Francis Crick Institute, a £700M newly constructed world-class biomedical institute located in the heart of central London.
Collaborator Contribution Imperial are completing the construction of the Michael Uren Biomedical Engineering Research Hub, a 13-storey building comprising state-of-the-art laboratory and office facilities for the next generation of biomedical engineering research. i-sense2 activities will be offered half a floor within the Hub, where research towards the developing biosensing technologies can be executed. This is equivalent to an in-kind building infrastructure contribution of £5M. Imperial can confirm that the Department of Bioengineering will prioritise the recruitment of an external candidate to a lectureship in biosensing/diagnostics. This is an in-kind contribution of £400,000 over 5 years, including start-up funds. Imperial's Department of Bioengineering will underwrite a minimum of four 3.5-year PhD studentships in the area of nanomaterial-based research for diagnostics (value £300,000).
Impact he nanomaterials-based designs from the Stevens programme developed in this consortium are high impact. Further investment would greatly support their validation in the field and contribute towards their optimal use as biosensors at the point-of-care. Publications from the programme based on these technologies have been published in Science, ACS Sensors and Nanoscale, while several others are being completed. Their demonstrated capability of a point-of-care technology in Uganda in 2015 is extraordinary and shows the potential for these approaches as viable tools for the biosensing and healthcare communities. Overall the "i-sense" consortium performed exceptionally well and is prepared to continue to research innovative biosensing and mobile network-based approaches to combating infectious diseases. Imperial College fully supports this i-sense2 proposal as the next step to continue pushing the forefront of the field to deliver technologies with real impact.
Start Year 2013
 
Description Francis Crick Institute 
Organisation Francis Crick Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution The Crick Institute has worked with this IRC since it began in 2013 . Since then we have added i-sense Flu meeting at the Institute of Materials in London and also at the i-sense seminar series. Also provided strategic advise.
Collaborator Contribution The Crick Institute is also interested to compare how their Google models compare to impact assessments that we measure at the World Influenza Centre e.g. from winter deaths and flu cases in ICU and in wards and would be happy to support Rachel in any new types of assessment. The value of this in-kind contribution - strategic advice, samples, to host students and data - which will not be charged to i-sense2, is estimated to be £5k.
Impact Crick closely believe the vision for the IRC to create a UK platform supporting the effective translation from lab to clinic of potentially game-changing early sensing systems for infections, with broad applicability to non-communicable diseases.
Start Year 2017
 
Description Mologic 
Organisation Mologic
Country United Kingdom 
Sector Private 
PI Contribution To research and identify advancements of diagnosing and online pathways for sexually transmitted diseases
Collaborator Contribution Materials (substrates, lateral flow based components)
Impact None as of yet
Start Year 2017
 
Description Newcastle University 
Organisation Newcastle University
Country United Kingdom 
Sector Academic/University 
PI Contribution Newcastle are collaborators led by Neil Keegan
Collaborator Contribution i) Newcastle University has created a cohort of Newcastle University Research Fellowships (NURFs). These are five year, tenure-track positions designed to convert promising early career independent scientists into full academic members, with more experienced academics providing support and guidance to aid our NURFs in establishing thriving research groups, writing successful grants and producing high quality publications. They are given a generous start-up package and we are prepared to support them financially for up to 5 years until they can bring in their own funding. They are set clear publication and grant funding targets for these 5 years and if these are met (externally validated) they will subsequently be given an open-ended appointment at the end of this term. Recruitment is dependent on evidence of existing 'star quality' respective to their peer group. As part of the NURF process, a salary line within their host research Institute has to be identified before the position can be advertised. For i-sense follow-on, a suitable salary line has been identified and agreed with the Director of the Institute of Cellular Medicine (ICM). This provides the opportunity to recruit a NURF within ICM in the area of molecular diagnostic technologies (value ~£300,000). The NURF would join the group as an independent researcher but would add to the critical mass of the group. ii) As part of capacity building in this area we can confirm that the University has recruited an external candidate to a lectureship in molecular diagnostic technologies who will start in Newcastle on 1st August 2017. iii) The Institute of Cellular Medicine will underwrite a 3 year PhD studentship in the area of Diagnostic and Therapeutic Technologies (value £70,000).
Impact The team has developed a bioinformatics pipeline (IDRIS) which, has targeted the rapid, specific detection of Clostridium difficile as well as, excitingly, providing proof of concept for the detection of other specific bacterial organisms, both Gram positive and Gram negative. Patent applications have been lodged for IDRIS system itself and antibodies against aF protein which is specific to all strains of C. difficile and which does not occur in closely related organisms. Publications are being held to be submitted as soon as a priority date for the patent applications has been secured. A spin-out company is a real possibility and the team are working closely with our Research and Enterprise team on an independent market analysis. The detection and diagnosis of specific bacterial infections facilitated by IDRIS is a major breakthrough in terms of rapid diagnostics but the next vital step in dealing with, or controlling, infection is effective treatment with antibiotics. Therefore the Newcastle team will investigate the adaptation of the IDRIS approach to target rapid systems for identification of antimicrobial resistance. We are committed to building upon our success by supporting the growth of Diagnostic Technologies for Healthcare and by retaining and further developing key research staff, - thus providing an impetus to i-sense which will contribute significantly towards sustainability.
Start Year 2013
 
Description Oxford Nanopore Technologies 
Organisation Oxford Nanopore Technologies
Country United Kingdom 
Sector Private 
PI Contribution Collaboration opportunities are around upstream protocol development and engineering of sample presentation, in the areas of TB and HIV, feasibility studies in collaboration with AHRI plus downstream analysis ie using machine learning techniques which are being developed by i-sense researchers.
Collaborator Contribution MinION Enhanced Starter Pack, a fully supported start to nanopore sequencing Potentially presentations at bi-annual meetings.
Impact MinION starter pack
Start Year 2017
 
Description Public Health England 
Organisation Public Health England
Country United Kingdom 
Sector Public 
PI Contribution PHE have worked closely with i-sense over the past five years, with a series of successful outcomes including the development of Google and Twitter tools that are intended to strengthen national surveillance of influenza through early warning; the use of social media to evaluate the community impact of a new paediatric influenza vaccination programme and Exploratory projects to determine the feasibility of self-testing through a web-enrolled cohort and the cost-effectiveness of near patient testing for managing seasonal and pandemic influenza. Through fur the r collaboration including joint studentships between PHE and the other IRC partners, i-sense2 intends to extend these approaches to predictive modelling for influenza and to other emerging infections.
Collaborator Contribution PHE would envisage at this stage that the contribution in-kind from PHE, in in terms of my own time for consultancy and attendance of bi-monthly progress meetings, and that of the lab would be estimated as contribution in-kind over the period of the i-sense follow-on project.
Impact PHE have worked closely with i-sense over the past five years, with a series of successful outcomes including the development of Google and Twitter tools that are intended to strengthen national surveillance of influenza through early warning
Start Year 2013
 
Description Royal College of General Practitioners 
Organisation Royal College of General Practitioners
Country United Kingdom 
Sector Academic/University 
PI Contribution i-Sense has investigated how the network of primary care data can be supplemented with syndromic data derived from Twitter and Google search logs. This approach, using RCGP RSC data for machine learning purpose, was evaluated by PHE, and is very likely to be incorporated into PHE's weekly influenza reports for the 2017/18 flu season. RCGP RSC data has also been used in a very innovative method to assess the effectiveness of a PHE child influenza vaccination pilot. Once again RCGP data was used to train models based on Twitter, Google, and Microsoft Bing data to estimate influenza prevalence in both pilot and control regions. This work was reported in a paper entitled "Assessing the Impact of a Health Intervention via User-generated Internet Content", published in Data Mining and Knowledge Discovery, Volume 29, Issue 5, Page 1434-1457, 2015.
Collaborator Contribution The Royal College of General Practitioners (RCGP) has a access to regularly updated primary care data based on our network of 200 Research and Surveillance Centre (RSC) practices, encompassing approximately 1.5m patient datasets all pseudoannonymised and downloaded on a weekly basis. This data is used for a variety of approved public health and research purposes, including estimation of the prevalence of influenza on the general population for Public Health England (PHE). Raw data are kept on the RCG RSC data and analytics hub at University of Surrey. This network complies with NHS requirements for a secure network and personal data does not leave this network.
Impact All data provision will follow RCGP RSC data approval processes to ensure secure network protocols are met.
Start Year 2017
 
Description Telefonica 
Organisation O2 Telefonica Europe plc
Country United Kingdom 
Sector Private 
PI Contribution A strong research team which does research and field testing. There are now opportunities to scale up the testing and healthcare prevention to a systems level
Collaborator Contribution Advisory and Steering group representation on digital technologies & industrial links to key players
Impact Strategic guidance on the Advisory Board
Start Year 2016
 
Description University College Hospitals, London 
Organisation University College London Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution Used clinical data for sequencing and dashboards
Collaborator Contribution Provided clinical data for analysis
Impact TBC
Start Year 2015
 
Description University of California, LA 
Organisation University of California, Los Angeles (UCLA)
Country United States 
Sector Academic/University 
PI Contribution UCLA have been collaborating with i-sense for approximately 2 years now, and have already hosted two graduate students from Prof. McKendry's lab to transfer some of our lab's expertise on mobile phone based sensing and diagnostics technologies toward infectious disease surveillance. Prior to this, UCLA also had an opportunity to visit UCL's lab in 2014 and presented at the i-sense EPSRC IRC New Frontiers in Digital Technologies for Influenza workshop that she organized at the Institute of Materials in London.
Collaborator Contribution As an i-sense2 Project Partner UCLA will contribute to the design and prototyping of novel smartphone connected photonic diagnostic tests developed in partnership with i-sense and hosting students. In turn, I look forward to the opportunity to work together on pilot studies of these devices in the UK and South Africa, write joint papers and new grant proposals together.
Impact Collaborations on the use of computational imaging, sensing and diagnostics technologies for mobile health, infectious disease screening and related applications.
Start Year 2014
 
Description University of Surrey 
Organisation University of Surrey
Country United Kingdom 
Sector Academic/University 
PI Contribution Surrey is a research collaborator on the i-sense 2
Collaborator Contribution Also, developed test-beds for health care with industrial partners Huawei, Os, BT/EE, 3, BBC, McLaren & NHS
Impact Surrey will be recruiting a Professor and Lecturer specifically into the e-health space and this equates to an investment of some £200,000 as part of our research support. For priming our research theme activities we have also committed £100,000 per annum to our Innovation for Health programme.
Start Year 2013
 
Description Discussion on use of mobile technologies to capture diagnostic data with WHO Global Laboratories Alliance for Diagnosis of High Threat Pathogens (GLAD-HD) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Other audiences
Results and Impact Deenan Pillay - Discussion on use of mobile technologies to capture diagnostic data with WHO Global Laboratories Alliance for Diagnosis of High Threat Pathogens (GLAD-HD)
Year(s) Of Engagement Activity 2019
 
Description Rachel McKendry Plenary Lecture at RCOG World Congress_June 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Plenary Lecture at RCOG World Congress
Year(s) Of Engagement Activity 2019
 
Description Rachel McKendry_Talk at 2019 NMC STI Workshop on Nanomechanical Sensors_Lausanne_June 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact In the 2019 edition we want to focus our workshop in two of the most promising fields: quantum and bio-sensing. We are putting together an exciting program with 8 keynote speakers and more than 10 invited speakers of the top international tier. We expect to attract around 150-200 people from all over the world. Very importantly, in our even we will put in contact two apparently very separate communities as are quantum and bio-sensing communities. The main objective during the workshop will be to explore the synergies between them. The School of Engineering of EPFL supports the organization of scientific workshops on the EPFL campus on topics of heightened interest at the forefront of research. These workshops attract highly visible and internationally recognizable speakers.
Year(s) Of Engagement Activity 2019
URL https://memento.epfl.ch/event/nmc-2019-sti-workshop-on-nanomechanical-sensors/
 
Description Rachel McKendry_Talk at Future of Individualized Medicine_San Diego_March 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact In 2019, the newly renamed Future of Individualized Medicine (formerly Future of Genomic Medicine) conference will expand to include additional perspectives on how to tailor medicine to the individual. Individualized medicine takes into account a person's genes-and genomics will remain a core topic for exploration and discussion-but it also considers the full spectrum of a person's uniqueness from their biologic, physiologic, anatomic, lifestyle and environmental information. The Future of Individualized Medicine conference will thus incorporate perspectives from the emerging fields of digital medicine, artificial intelligence and machine learning, behavioral science and others. This is truly a multidisciplinary forum designed to accelerate the transformation of medicine.
Year(s) Of Engagement Activity 2008,2019
URL https://www.scripps.edu/science-and-medicine/translational-institute/about/events/foim/
 
Description Talk at 2019 Chief Scientific Officer's Annual Conference_March 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Talk at 2019 Chief Scientific Officer's Annual Conference
Year(s) Of Engagement Activity 2019